Literature DB >> 21540845

Harnessing the potential of induced pluripotent stem cells for regenerative medicine.

Sean M Wu1, Konrad Hochedlinger.   

Abstract

The discovery of methods to convert somatic cells into induced pluripotent stem cells (iPSCs) through expression of a small combination of transcription factors has raised the possibility of producing custom-tailored cells for the study and treatment of numerous diseases. Indeed, iPSCs have already been derived from patients suffering from a large variety of disorders. Here we review recent progress that has been made in establishing iPSC-based disease models, discuss associated technical and biological challenges, and highlight possible solutions to overcome these barriers. We believe that a better understanding of the molecular basis of pluripotency, cellular reprogramming and lineage-specific differentiation of iPSCs is necessary for progress in regenerative medicine.

Entities:  

Mesh:

Year:  2011        PMID: 21540845      PMCID: PMC3617981          DOI: 10.1038/ncb0511-497

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  116 in total

1.  Efficient differentiation of human embryonic stem cells to definitive endoderm.

Authors:  Kevin A D'Amour; Alan D Agulnick; Susan Eliazer; Olivia G Kelly; Evert Kroon; Emmanuel E Baetge
Journal:  Nat Biotechnol       Date:  2005-10-28       Impact factor: 54.908

2.  High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells.

Authors:  Sabrina C Desbordes; Dimitris G Placantonakis; Anthony Ciro; Nicholas D Socci; Gabsang Lee; Hakim Djaballah; Lorenz Studer
Journal:  Cell Stem Cell       Date:  2008-06-05       Impact factor: 24.633

3.  Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution.

Authors:  Nimet Maherali; Rupa Sridharan; Wei Xie; Jochen Utikal; Sarah Eminli; Katrin Arnold; Matthias Stadtfeld; Robin Yachechko; Jason Tchieu; Rudolf Jaenisch; Kathrin Plath; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

4.  Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines.

Authors:  Steven J Kattman; Alec D Witty; Mark Gagliardi; Nicole C Dubois; Maryam Niapour; Akitsu Hotta; James Ellis; Gordon Keller
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

5.  Induced pluripotent stem cells generated without viral integration.

Authors:  Matthias Stadtfeld; Masaki Nagaya; Jochen Utikal; Gordon Weir; Konrad Hochedlinger
Journal:  Science       Date:  2008-09-25       Impact factor: 47.728

6.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

7.  In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Authors:  Marius Wernig; Alexander Meissner; Ruth Foreman; Tobias Brambrink; Manching Ku; Konrad Hochedlinger; Bradley E Bernstein; Rudolf Jaenisch
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

8.  Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts.

Authors:  Rutger-Jan Swijnenburg; Sonja Schrepfer; Johannes A Govaert; Feng Cao; Katie Ransohoff; Ahmad Y Sheikh; Munif Haddad; Andrew J Connolly; Mark M Davis; Robert C Robbins; Joseph C Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

9.  Somatic coding mutations in human induced pluripotent stem cells.

Authors:  Athurva Gore; Zhe Li; Ho-Lim Fung; Jessica E Young; Suneet Agarwal; Jessica Antosiewicz-Bourget; Isabel Canto; Alessandra Giorgetti; Mason A Israel; Evangelos Kiskinis; Je-Hyuk Lee; Yuin-Han Loh; Philip D Manos; Nuria Montserrat; Athanasia D Panopoulos; Sergio Ruiz; Melissa L Wilbert; Junying Yu; Ewen F Kirkness; Juan Carlos Izpisua Belmonte; Derrick J Rossi; James A Thomson; Kevin Eggan; George Q Daley; Lawrence S B Goldstein; Kun Zhang
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

10.  Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

Authors:  Gabsang Lee; Eirini P Papapetrou; Hyesoo Kim; Stuart M Chambers; Mark J Tomishima; Christopher A Fasano; Yosif M Ganat; Jayanthi Menon; Fumiko Shimizu; Agnes Viale; Viviane Tabar; Michel Sadelain; Lorenz Studer
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

View more
  204 in total

Review 1.  Phenotyping patient-derived cells for translational studies in cardiovascular disease.

Authors:  Stanley Y Shaw; Ari D Brettman
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

2.  Evolution of iPSC disease models.

Authors:  Weiqi Zhang; Zhichao Ding; Guang-Hui Liu
Journal:  Protein Cell       Date:  2012-01       Impact factor: 14.870

3.  Non-viral iPSCs: a safe way for therapy?

Authors:  Weiqi Zhang; Di Guan; Jing Qu; Weizhou Zhang; Guang-Hui Liu
Journal:  Protein Cell       Date:  2012-04       Impact factor: 14.870

Review 4.  Cellular reprogramming: a new technology frontier in pharmaceutical research.

Authors:  Amy Brock; Hui-Tong Goh; Binxia Yang; Yu Lu; Hu Li; Yuin-Han Loh
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

Review 5.  miRNAs involved in the generation, maintenance, and differentiation of pluripotent cells.

Authors:  Nils Pfaff; Thomas Moritz; Thomas Thum; Tobias Cantz
Journal:  J Mol Med (Berl)       Date:  2012-06-09       Impact factor: 4.599

6.  Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα.

Authors:  C Bueno; J L Sardina; B Di Stefano; D Romero-Moya; A Muñoz-López; L Ariza; M C Chillón; A Balanzategui; J Castaño; A Herreros; M F Fraga; A Fernández; I Granada; O Quintana-Bustamante; J C Segovia; K Nishimura; M Ohtaka; M Nakanishi; T Graf; P Menendez
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

7.  Reconstituting Mouse Lungs with Conditionally Reprogrammed Human Bronchial Epithelial Cells.

Authors:  Ryan LaRanger; Jennifer R Peters-Hall; Melissa Coquelin; Busola R Alabi; Christopher T Chen; Woodring E Wright; Jerry W Shay
Journal:  Tissue Eng Part A       Date:  2017-09-25       Impact factor: 3.845

Review 8.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

Review 9.  Mechanisms underlying the formation of induced pluripotent stem cells.

Authors:  Federico González; Danwei Huangfu
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-09-18       Impact factor: 5.814

Review 10.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.